MD at a glance
Pediatrix Medical Group, Inc. (MD, SEC CIK 893949) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Pediatrix Medical Group, Inc. (MD) reported revenue of $1.9 billion (down 4.9% from FY2024) and net income of $165.4 million. Diluted EPS was $1.94.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Pediatrix Medical Group, Inc. (MD) shares worth $1.1 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.9B
- −4.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 31 funds
- $1.1B · −1 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: provider of neonatal and pediatric healthcare services
- No new products, services, or segments introduced or emphasized this year
- No stated strategic shift or changed competitive positioning vs prior year
- 144 holders of record of common stock as of February 13, 2026; stock price $21.52 per share
- No dividends declared or paid in 2023-2025; dividend payments limited by credit agreement
Risk Factors
- Regulatory/legal risk: potential audit, inquiry, or investigation impact on revenue from government agencies over $1.15B gross receivables and DSO 42.8 days
- Geopolitical/macro risk: 32% of net revenue concentrated in Texas exposing Pediatrix to regional health policy or economic shifts
- Operational/supply chain risk: transformation and restructuring expenses $22.3M in 2025 due to shared services position eliminations and revenue cycle transitions
- Competitive/market disruption risk: practice dispositions reducing net revenue by $99.1M or 4.9% in 2025, affecting market footprint and growth
- Financial/structural risk: goodwill impairment charge of $150.6M in 2024 reflecting valuation sensitivity to market capitalization and stock price declines
Management Discussion & Analysis
- Profitability or margin changes not specified in provided text
- Segment details: 1,350 neonatal physicians, 475 maternal-fetal, 230 pediatric intensive care, 220 hospital-based pediatric, 20 pediatric surgical
- No cash flow, buybacks, dividends, or capex info given
- Risks: potential revenue impact from shifts toward government healthcare programs due to economic/demographic changes and rising bad debt from patient payment difficulties
AI summary of the MD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes to risk factors previously disclosed in the 2025 Form 10-K
- Share-repurchase exposure: $145.5 million repurchased under the August 18, 2025 program as of June 30, 2026
- Regulatory cost: 1% excise tax on share repurchases under the Inflation Reduction Act of 2022
- Market risk: future repurchases dependent on general economic and market conditions
AI summary of the MD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Second-quarter release covers operations for three and six months ended June 30, 2026
- Results details are contained in Exhibit 99.1, providing the primary basis for assessing quarterly performance
Item EX-99.1: Item EX-99.1
- Q2 revenue $487.8M, up 4.0% YoY, driven by acquisitions and reimbursement gains despite 2.1% lower same-unit volume
- Adjusted EPS $0.63 vs $0.53, while diluted shares fell to 81.4M from 85.5M after repurchases
Item 7.01: Regulation FD Disclosure
- David Haddock appointed Executive Vice President, General Counsel and Secretary
- Appointment strengthens legal leadership and corporate governance oversight
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Mary Ann E. Moore departing October 31, 2026 from EVP, General Counsel, Chief Administrative Officer and Secretary roles
- Advisory role continues through October 31, 2026, supporting leadership transition
Item EX-99.1: Item EX-99.1
- Q2 2026 payor mix remained stable, with no unfavorable shifts reported by other healthcare companies
- No material changes in net revenue trends versus recent historical periods, reducing near-term reimbursement risk
AI summaries of MD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MD
Don't miss the next MD filing
- Alerts as it files. A push when MD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MD, by share count.
- Ask anything. An AI agent that reads every MD filing and answers with sources.
MD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Linynsky Laura A | D | Sep 10, 2026 | 6,000 | $26.82 |
| Young Sylvia Jean | D | Aug 14, 2026 | 18,500 | $26.62 |
| SANSONE GUY P | A | Aug 12, 2026 | 472 | $26.50 |
| Young Sylvia Jean | A | Aug 12, 2026 | 472 | $26.50 |
| Linynsky Laura A | A | Aug 12, 2026 | 472 | $26.50 |
| Rucker Michael A. | A | Aug 12, 2026 | 472 | $26.50 |
| Newman Kurt Douglas | A | Aug 12, 2026 | 472 | $26.50 |
| Weis Shirley A | A | Aug 12, 2026 | 472 | $26.50 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $2.0B | $2.0B | $1.9B |
| Operating Income | $7.3M | -$68.7M | $208.8M |
| Net Income | - | -$99.1M | $165.4M |
| Op. Margin | 0.4% | -3.4% | 10.9% |
| Net Margin | - | -4.9% | 8.6% |
| Balance Sheet | |||
| Total Assets | $2.2B | $2.2B | $2.2B |
| Equity | $849.1M | $764.9M | $865.9M |
| ROE | - | -13.0% | 19.1% |
| Per Share | |||
| EPS | $0.73 | $-1.19 | $1.94 |
| Cash Flow | |||
| Operating CF | $137.3M | $206.6M | $271.1M |
Source: XBRL data in Pediatrix Medical Group, Inc. (MD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $1.10B |
| Q1 2026 | 32 | $952.9M |
| Q4 2025 | 31 | $972.8M |
| Q3 2025 | 30 | $782.7M |
| Q2 2025 | 29 | $663.9M |
| Q1 2025 | 27 | $467.3M |
| Q4 2024 | 24 | $382.4M |
| Q3 2024 | 21 | $185.0M |
- Dimensional Fund Advisors+363.4K (+9%)
- Invesco Ltd+251.4K (+27%)
- State Street Corp+154.7K (+5%)
- BlackRock+139.9K (+1%)
- Raymond James Financial+108.7K (+24%)
- FMR LLC (Fidelity)−1.53M (-67%)
- Renaissance Technologies LLC−245.0K (-16%)
- Vanguard Portfolio Management LLC−169.0K (-3%)
- D.E. Shaw & Co−95.3K (-6%)
- AQR Capital Management−89.3K (-16%)
- Millennium Management+55.1K
- Citadel Advisors LLC−73.0K
- Mangrove Partners−18.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 225 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 14, 2026 | - | - | - |
| SC 13G | Sep 3, 2026 | - | - | |
| SC 13G | Sep 3, 2026 | - | - | |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| SC 13G | Jul 14, 2026 | - | - | |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - |
Related Health Care companies
- EHC · Encompass Health CorpServices-Hospitals
- SEM · SELECT MEDICAL HOLDINGS CORPServices-Hospitals
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
MD SEC filings: frequently asked questions
Which institutions hold MD stock?
As of June 30, 2026, the largest Pediatrix Medical Group, Inc. (MD) holders among the 13F filers tracked by SignalX were BlackRock ($347.4 million), Vanguard Portfolio Management LLC ($151.6 million), Dimensional Fund Advisors ($106.9 million), Vanguard Capital Management LLC ($91.7 million), State Street Corp ($89.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Pediatrix Medical Group, Inc. (MD) reported revenue of $1.9 billion (down 4.9% from FY2024) and net income of $165.4 million. Diluted EPS was $1.94. The figures come from the XBRL data in the 10-K.
What are the main risks in MD's latest 10-K?
In the 10-K filed February 19, 2026, Pediatrix Medical Group, Inc. (MD) flagged: Regulatory/legal risk: potential audit, inquiry, or investigation impact on revenue from government agencies over $1.15B gross receivables and DSO 42.8 days. Geopolitical/macro risk: 32% of net revenue concentrated in Texas exposing Pediatrix to regional health policy or economic shifts. (AI summary of the Risk Factors section.)
What did MD report in its latest 8-K?
Pediatrix Medical Group, Inc. (MD) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Second-quarter release covers operations for three and six months ended June 30, 2026.
What are the latest MD SEC filings?
Pediatrix Medical Group, Inc. (MD) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 14, 2026.
What is MD's SEC CIK number?
Pediatrix Medical Group, Inc. (MD)'s SEC Central Index Key (CIK) is 893949. EDGAR lists every MD filing under that number.
Ask anything about MD
The research agent reads MD's filings, financials, insider trades and 13F holders, then answers with sources.